ClinicalTrials.gg
CompletedNCT02923947Updated Nov 27, 2023

Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment

A Phase 1 interventional study of Osimertinib; AZD9291 in Solid Tumours, sponsored by AstraZeneca. Completed at 11 sites in 3 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-11-27.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies in Renal Insufficiency by AstraZeneca — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · AstraZeneca.

Enrollment
21st of 29
16 · median 24
Started
2017
with 1 other
Phase 1
26 of 29
none open now
Registered
12th of 29
by date

Among the 29 studies in Renal Insufficiency by AstraZeneca, this one is the 21st largest by enrollment, is one of 2 that started in 2017, is one of 26 in phase 1, and was the 12th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 29 studies in Renal Insufficiency by AstraZeneca is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Renal Insufficiency by AstraZeneca as a file.
02

Study summary

The purpose of this study is to assess the effect of severe renal impairment on the levels of AZD9291 in the blood in patients with advanced solid tumours compared to patients with normal renal function

Read the detailed description

This is a 3-part study (Part A, Part B and continued access) in patients with advanced solid tumours (excluding lymphoma) that are refractory to standard therapies or for which no standard therapies exist.

Part A will have a non-randomised, open-label, parallel group, multi-centre design to investigate the pharmacokinetics (PK) of a single dose of osimertinib in patients with severe renal impairment compared with patients with normal renal function. Patients with severe renal impairment will be recruited before those with normal renal function to allow the cohorts to be matched as closely as possible in terms of demographic characteristics (ie, age, body mass index [BMI] and sex).

Approximately 16 patients (8 with severe renal impairment and 8 with normal renal function) are planned to be enrolled to obtain at least 12 evaluable patients (6 with severe renal impairment and 6 with normal renal function) in Part A. A patient with severe renal impairment (as measured by the Cockcroft-Gault equation) is defined as having a creatinine clearance (CrCl) of \<30 mL/min whilst a patient with normal renal function has a CrCl of ≥90 mL/min. Both the severe renal impairment and normal renal function patients will be recruited such that both groups will be matched for age, sex, and BMI to the maximum extent possible.

In Part A, each patient will receive a single oral dose of osimertinib 80 mg (given as a tablet). Where possible, patients will check into the clinic on Day -1, the evening prior to dosing (Day 1), and remain resident until 24 hours after the dose of osimertinib (Day 2) for collection of blood samples and 24-hour pooled urine for PK analysis during this time. Samples will be analysed to determine the concentrations of osimertinib and metabolites (AZ5104 and AZ7550) in plasma, urine, and plasma ultrafiltrate (PUF). Patients will then return to the clinic as outpatients for assessments on Day 3 (48 hours), Day 4 (72 hours), Day 6 (120 hours), Day 8 (168 hours) and Day 10 (216 hours).

Part B will allow patients with severe renal impairment, who complete Part A, to continue to receive osimertinib 80 mg once daily for 12 weeks and will provide additional safety data. Patients should start Part B after the last PK sample collected in Part A (ie, 216 hours after receiving the single dose of osimertinib in Part A).

If a patient does not immediately continue into Part B, this should be discussed on a case by case basis with the AstraZeneca physician or representative. Patients who enter Part B, will have weekly clinic visits for the first 3 weeks; thereafter visits will be every 3 weeks until Week 12. Safety assessments will be collected and there will be no formal evaluation of efficacy.

At the end of Part B, those patients with severe renal impairment who are deemed to be gaining clinical benefit from osimertinib will enter the continued access phase. Patients with normal renal function can enter the continued access phase immediately after completing Part A (ie, collection of the last PK sample scheduled on Day 10 of Part A). During the continued access phase, patients may continue to take osimertinib 80 mg once daily, if patients and the Investigator deem it appropriate, or until such time as their disease progresses, the Investigator believes the patients are no longer deriving clinical benefit, or patients stop taking osimertinib for any other reason. No clinical data, other than serious adverse events (SAEs) that may be related to the investigational product (IP), will be collected during this phase.

03

Conditions studied

  • Solid Tumours

Browse trials for

Keywords

  • Pharmacokinetics,
  • Renal impairment,
  • Safety assessments,
  • Solid tumours,
  • EGFRm+
  • EGFRm+/T790M+ inhibitor
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. For inclusion as a patient with severe renal impairment patient must have stable severe renal impairment ( \<30 mL/min at screening), for at least 2 months prior to the study.
  2. For inclusion as a patient with normal renal function, patient must have CrCl ≥90 mL/min at screening.
  3. >18 years old
  4. Histological or cytological confirmation of a solid, malignant tumour (excluding lymphoma) that is to standard therapies or for which no standard therapies exist. Tumours in which inhibition of the EGFR pathway is considered relevant by the Investigator are not mandated but are encouraged.
  5. performance status ≤2
  6. of ≥12 weeks
  7. 18-35.
  8. Females should be using adequate measures and must have a negative pregnancy test prior to dosing if of or must have evidence of non-child bearing potential
  9. Males should use barrier contraception until 6 months after the last study drug is taken.

Exclusion criteria

Exclusion criteria

  1. Participation in another clinical study with an IP during the last 14 days (or a longer period, depending on the agents used).
  2. Treatment with any of the following:

    • Treatment with a 1st or 2nd generation EGFR-TKI within 8 days or approximately 5 half-lives, prior to the first dose of study drug.
    • Any cytotoxic chemotherapy, agents or anticancer drugs within 14 days of the first dose of study drug.
    • Osimertinib in the present study or has previously received a 3rd generation EGFR-TKI (eg, CO 1686).
    • Major surgery within 4 weeks of the first dose of study drug.
    • Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment
    • Currently receiving medications or herbal supplements known to be potent inducers of . Patients in Part B and continued access must avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known potent inducer effects on CYP3A4.
  3. Patients with severe renal impairment only: use of concurrent medication known to affect within 7 days of the first dose
  4. Unresolved toxicities from prior therapy greater than Grade 1 at the time of starting study treatment; with the exception of alopecia and Grade 2 prior platinum-therapy related neuropathy
  5. Spinal cord compression or , unless asymptomatic, stable and not requiring for at least 4 weeks prior to start of study treatment
  6. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

    • \<1.5 x 109/L
    • count \<100 x 109/L
    • \<90 g/L
    • >2.5 times the if no demonstrable liver or >5xULN in the presence of liver metastases
    • AST >2.5xULN if no demonstrable liver metastases or > 5xULN in the presence of liver metastases
    • Total >1.5 times ULN if no liver metastases or >3xULN in the presence of liver metastases
  7. Any of the following cardiac criteria:

    • Mean resting QTcF >470 msec, obtained from 3 ECGs.
    • Abnormalities in rhythm, conduction or morphology of resting
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval
  8. Unable to swallow oral medication or patients with GI disorders or significant GI resection.
  9. Medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
  10. Severe portal hypertension or surgical porto-systemic shunts.
  11. Kidney transplant
  12. On dialysis
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Normal renal function

    For inclusion in the study as a patient with normal renal function, patients must have creatinine clearance ≥90 mL/min.

    Drug: Osimertinib; AZD9291

  • Experimental
    Severe renal impairment

    For inclusion in the study as a patient with severe renal impairment, patients must have stable severe renal impairment (creatinine clearance \<30 mL/min), as defined by the Cockcroft Gault equation, for at least 2 months prior to Day 1.

    Drug: Osimertinib; AZD9291

Interventions

  • 80mg tablet dose to be taken orally - single dose in part A, daily dosing in Part B and continued access until progression or no longer receiving benefit

    Also known as: TAGRISSO™

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from zero to infinity for osimertinib

    Part A: To investigate the PK of osimertinib after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs post-dose

  2. Maximum plasma concentration for osimertinib

    Part A: To investigate the PK of osimertinib after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs post-dose

Secondary outcomes

  1. Area under the plasma concentration-time curve from zero to the last quantifiable time point for osimertinib

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  2. Area under the plasma concentration-time curve from zero to 24 hours post-dose for osimertinib

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24hrs for osimertinib post-dose

  3. Time to maximum plasma concentration for osimertinib

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  4. Apparent clearance following oral administration for osimertinib

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  5. Apparent volume of distribution for osimertinib

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  6. Terminal rate constant for osimertinib

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  7. Terminal half-life for osimertinib

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  8. Amount excreted in urine from time zero to 24 hours post-dose for osimertinib

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24hrs for osimertinib post-dose

  9. Renal clearance for osimertinib

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24hrs post-dose for osimertinib plasma and 24 hour urine collection.

  10. Maximum plasma concentration for AZ5104

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  11. Maximum plasma concentration for AZ7550

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  12. Time to maximum plasma concentration for AZ5104

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  13. Time to maximum plasma concentration for AZ7550

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  14. Area under the plasma concentration time curve from zero to infinity for AZ5104

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  15. Area under the plasma concentration time curve from zero to infinity for AZ7550

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  16. Area under the plasma concentration-time curve from zero to the last quantifiable time point for AZ5104

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  17. Area under the plasma concentration-time curve from zero to the last quantifiable time point for AZ7550

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  18. Amount excreted in urine from time zero to 24 hours post-dose for AZ5104

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: 24 hour pooled collection starting from time of dosing on Day 1

  19. Amount excreted in urine from time zero to 24 hours post-dose for AZ7550

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: 24 hour pooled collection starting from time of dosing on Day 1

  20. Terminal rate constant for AZ5104

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  21. Terminal rate constant for AZ7550

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  22. Terminal half-life for AZ5104

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  23. Terminal half-life for AZ7550

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  24. Renal clearance for AZ5104

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24hrs post-dose for AZ5104 plasma and 24 hour urine collection.

  25. Renal clearance for AZ7550

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24 hours post-dose for AZ7550 plasma and 24 hour urine collection.

  26. Metabolite to parent ratios for maximum plasma concentration

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  27. Metabolite to parent ratios for area under the plasma concentration time curve from zero to infinity

    Part A: To investigate the PK of osimertinib and metabolites (AZ5104 and AZ7550) after a single oral dose of 80 mg in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: On Day of dosing in Part A - predose, 1, 2, 4, 6, 8, 10, 24, 48, 72, 120, 168, 216hrs for osimertinib post-dose

  28. Part A: Adverse Events's, graded by the National Cancer Institute Common Terminology Criteria for Adverse Event's (CTCAE v4.0)

    Part A: To investigate the safety and tolerability of a single oral dose of osimertinib in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: Until 30 days following the final dose of osimertinib

  29. Part A: physical exam

    Part A: To investigate the safety and tolerability of a single oral dose of osimertinib in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: Until 30 days following the final dose of osimertinib

  30. Part A: vital signs

    Part A: To investigate the safety and tolerability of a single oral dose of osimertinib in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: Until 30 days following the final dose of osimertinib

  31. Part A: ECG

    Part A: To investigate the safety and tolerability of a single oral dose of osimertinib in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: Until 30 days following the final dose of osimertinib

  32. Part A: evaluation of laboratory

    Part A: To investigate the safety and tolerability of a single oral dose of osimertinib in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: Until 30 days following the final dose of osimertinib

  33. Part A: echocardiogram/MUGA.

    Part A: To investigate the safety and tolerability of a single oral dose of osimertinib in patients with advanced solid tumours and normal renal function or severe renal impairment.

    Time frame: Until 30 days following the final dose of osimertinib

  34. Part B - Adverse events, graded CTCAE v4.0

    Part B: To investigate the safety and tolerability of multiple oral doses of osimertinib in patients with advanced solid tumours and severe renal impairment.

    Time frame: Until 30 days following the final dose of osimertinib

  35. Part B -physical exam

    Part B: To investigate the safety and tolerability of multiple oral doses of osimertinib in patients with advanced solid tumours and severe renal impairment.

    Time frame: Until 30 days following the final dose of osimertinib

  36. Part B - vital signs

    Part B: To investigate the safety and tolerability of multiple oral doses of osimertinib in patients with advanced solid tumours and severe renal impairment.

    Time frame: Until 30 days following the final dose of osimertinib

  37. Part B - ECG

    Part B: To investigate the safety and tolerability of multiple oral doses of osimertinib in patients with advanced solid tumours and severe renal impairment.

    Time frame: Until 30 days following the final dose of osimertinib

  38. Part B - evaluation of laboratory parameters.

    Part B: To investigate the safety and tolerability of multiple oral doses of osimertinib in patients with advanced solid tumours and severe renal impairment.

    Time frame: Until 30 days following the final dose of osimertinib

07

Study locations

11 sites
  • Research Site
    Angers Cedex 2, 49055, France
  • Research Site
    Bordeaux, 33000, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Lille Cedex, 59020, France
  • Research Site
    Saint Herblain, 44805, France
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Madrid, 28050, Spain
  • Research Site
    Sevilla, 41013, Spain
08

References and documents

Publications

  • Vishwanathan K, Sanchez-Simon I, Keam B, Penel N, de Miguel-Luken M, Weilert D, Mills A, Marotti M, Johnson M, Ravaud A. A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment. Pharmacol Res Perspect. 2020 Aug;8(4):e00613. doi: 10.1002/prp2.613. PubMed 32567817 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Sep 2018, 16 months.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 16 months is above that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2016
First posted
Oct 5, 2016
StartActual
May 4, 2017
Primary completionActual
Sep 20, 2018
CompletionActual
Oct 28, 2022
Last update
Nov 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02923947
Lead sponsor
AstraZeneca
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Oct 5, 2016
Start date
May 4, 2017
Primary completion
Sep 20, 2018
Completion
Oct 28, 2022
Last update
Nov 27, 2023

Study contacts

Philippe Ravaud, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion